Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,092 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Health Literacy and Smoking Cessation in Low-SES Diverse Smokers - Project HALT II

NCT02942212
View directory record Official record
Conditions
Smoking Cessation
Interventions
Questionnaire, In-Depth Interviews, Breath Test, Nicotine Patches, Advice plus Phone Counseling, Advice plus Counseling Sessions, Self Assessment Questionnaires
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 9, 2026, 5:40 AM EDT
Active, not recruiting Phase 2 Interventional

Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

NCT02494700
View directory record Official record
Conditions
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage I Mantle Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage II Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma, Ocular Adnexal Lymphoma, Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma, Orbit Lymphoma
Interventions
External Beam Radiation Therapy, Orbital Radiation
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes

NCT01681875
View directory record Official record
Conditions
Tobacco Dependence
Interventions
very low nicotine content cigarettes
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
9
States / cities
San Francisco, California • Tampa, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 9, 2026, 5:40 AM EDT
Terminated Phase 1 Interventional

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

NCT04526795
View directory record Official record
Conditions
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent T-Cell Prolymphocytic Leukemia, Refractory Acute Biphenotypic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory T-Cell Prolymphocytic Leukemia
Interventions
Cytarabine, Fludarabine, Pegcrisantaspase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 9, 2026, 5:40 AM EDT
Recruiting No phase listed Observational

Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract

NCT07789119
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
biospecimen Collection
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

NCT02257541
View directory record Official record
Conditions
Advanced Gastrointestinal Stromal Tumor (GIST)
Interventions
BGJ398, Imatinib Mesylate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
7
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 9, 2026, 5:40 AM EDT
Active, not recruiting No phase listed Observational

ProvoxLife Adoption Trends for Heat-Moisture Exchanger

NCT05036330
View directory record Official record
Conditions
Malignant Head and Neck Neoplasm
Interventions
Clinical Evaluation, Physical Examination, Quality-of-Life Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Terminated Phase 1 Interventional

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

NCT01430351
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
Mefloquine, Memantine Hydrochloride, Metformin Hydrochloride, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 9, 2026, 5:40 AM EDT
Not listed Phase 2 Interventional Results available

Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

NCT03094637
View directory record Official record
Conditions
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome
Interventions
Azacitidine, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 9, 2026, 5:40 AM EDT
Not listed No phase listed Observational

Obesity: Cancer Risk Among African Americans

NCT01294657
View directory record Official record
Conditions
Cancer, Obesity
Interventions
Health Education, MAPS
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

NCT01725165
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, External Beam Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Standard Follow-Up Care, Therapeutic Conventional Surgery
Other · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

NCT00614653
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Bevacizumab, Erlotinib, Capecitabine, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of CC-5013 in Myelofibrosis

NCT00087672
View directory record Official record
Conditions
Myelofibrosis
Interventions
CC-5013
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma

NCT02057445
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Lymphoproliferative Disorder
Interventions
EBV CTL's, Peripheral Blood Donor
Drug · Other
Lead sponsor
New York Medical College
Other
Eligibility
1 Year and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea

NCT01832402
View directory record Official record
Conditions
Advanced Cancers
Interventions
Fentanyl Pectin Nasal Spray, Placebo Nasal Spray, Walk Test, Questionnaires, Mental Ability Tests
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 9, 2026, 5:40 AM EDT
Active, not recruiting Early Phase 1 Interventional

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

NCT02744053
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Scintimammography, Technetium Tc-99m Sestamibi
Procedure · Other · Radiation + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
6
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Active, not recruiting Not applicable Interventional

NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer

NCT04986670
View directory record Official record
Conditions
Lung Cancer, Small Cell, Lung Cancer Metastatic, Lung Cancer Recurrent, Treatment Side Effects, Lung Cancer, Non-small Cell, Nutritional Imbalance
Interventions
Nutritional Counseling, Medically Tailored Meals (MTMs), Nutrition Prescription, Nutrition Assessment, Nutrition Toolkit, Monthly Emails
Behavioral · Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 100 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

NCT04188405
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Decitabine, Ponatinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

NCT01927731
View directory record Official record
Conditions
Bone Marrow Transplantation Recipient, Cord Blood Transplant Recipient, Hematopoietic Cell Transplantation Recipient
Interventions
Eltrombopag Olamine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 9, 2026, 5:40 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stage I/II Nasal NK Cell Lymphoma

NCT01321008
View directory record Official record
Conditions
Lymphoma
Interventions
Radiation, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Oct 9, 2026, 5:40 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Patient and Caregiver Attitudes and Beliefs Regarding Prescription of Intranasal Naloxone Spray for Opioid Overdose

NCT04129138
View directory record Official record
Conditions
Caregiver, Patient
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

NCT02907099
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
CXCR4 Antagonist BL-8040, Pembrolizumab, Pharmacological Study
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 9, 2026, 5:40 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Couples-Based Yoga Program in Improving Quality of Life in Patients With High-Grade Glioma Undergoing Radiation Therapy and Their Partners

NCT02481349
View directory record Official record
Conditions
Caregiver, Glioma
Interventions
Best Practice, Informational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Yoga
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Terminated Phase 2 Interventional Results available

Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

NCT00656916
View directory record Official record
Conditions
Bronchiolitis
Interventions
Fluticasone Propionate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 9, 2026, 5:40 AM EDT